ArticleBMC infectious diseases2026
Dysregulated m6A RNA methylation in tuberculosis: association with altered methyltransferase expression and immune responses.
Article in BMC infectious diseases, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
objectiveTuberculosis (TB) remains a global health threat with an incompletely understood pathogenesis. The RNA epigenetic modification N6-methyladenosine (m6A) is a key regulator of immune responses in various diseases, but its role in human TB is largely unexplored. This study aimed to investigate the involvement of m6A modification in TB by profiling its dynamics and the expression of its regulatory enzymes in clinical cohorts.
methodIn this cross-sectional study, 105 participants were enrolled and classified into four groups based on clinical and laboratory findings: microbiologically-confirmed pulmonary tuberculosis (PTB), interferon-gamma release assay positive (IGRAs-positive), healthy controls (HC), and symptomatic controls (SC). Nutritional, inflammatory, and immunological indicators, including total protein (TP), albumin (ALB), prognostic nutritional index (PNI), Lymphocyte (LY), Neutrophil (NE), platelet-to-lymphocyte ratio (PLR), and neutrophil-to-lymphocyte ratio (NLR), were collected. Circulating m6A levels were systematically evaluated using highly sensitive methods, and the mRNA expression of key m6A regulators (writers: METTL3/14, WTAP; eraser: FTO, ALKBH5; reader: YTHDF2) were quantified via quantitative real-time reverse transcription polymerase chain reaction (qRT-PCR).
resultsCompared with the HC group, the PTB and IGRAs-positive groups showed significantly decreased LY%, TP, ALB, and PNI, along with increased NE%, PLR, and NLR (P < 0.05). No significant difference in m6A levels was observed between the HC and SC groups. However, m6A levels in the PTB and IGRAs-positive groups were significantly lower than those in the HC group and were positively correlated with clinical indicators reflecting immune response status (P < 0.05). Moreover, m6A methyltransferases exhibited distinct expression patterns across groups with different infection statuses, suggesting a key regulatory role in immune responses.
conclusionOur study unveils a significant reduction in m6A modification and a dysregulated expression of its regulatory enzymes during Mycobacterium tuberculosis infection, which correlates with altered immune-nutritional status. These findings position m6A modification as a novel immunomodulatory mechanism in TB pathogenesis, offering fresh insights into the epitranscriptomic landscape of TB and providing a rationale for future research into its translational relevance.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.